Compare FANG & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FANG | BDX |
|---|---|---|
| Founded | 2007 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.1B | 51.5B |
| IPO Year | 2012 | 1995 |
| Metric | FANG | BDX |
|---|---|---|
| Price | $213.64 | $146.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 24 | 13 |
| Target Price | ★ $213.82 | $186.00 |
| AVG Volume (30 Days) | ★ 2.6M | 2.5M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | 2.05% | ★ 2.89% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.73 | 1.34 |
| Revenue | $15,026,000,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | $12.05 | N/A |
| Revenue Next Year | N/A | $3.02 |
| P/E Ratio | ★ $37.27 | $109.50 |
| Revenue Growth | ★ 35.79 | 8.24 |
| 52 Week Low | $127.75 | $144.51 |
| 52 Week High | $214.51 | $213.08 |
| Indicator | FANG | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 74.38 | 33.04 |
| Support Level | $136.77 | N/A |
| Resistance Level | N/A | $159.79 |
| Average True Range (ATR) | 5.41 | 3.35 |
| MACD | 2.04 | -0.30 |
| Stochastic Oscillator | 97.93 | 15.77 |
Diamondback is a crude oil and natural gas exploration and production firm whose operations represent a pure-play in the US Permian Basin. The company went public in 2012 and has established itself as a top-tier independent producer through disciplined acquisition and operational excellence. The company's most transformational transaction occurred in September 2024 with the completion of its $26 billion merger with Endeavor Energy Resources, which added around 470,000 net acres and doubled Diamondback's total acreage position. Diamondback boasts an enviable position in the Midland sub-basin, with some of the lowest unit costs among its Permian peers.
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. On a 2025 sales basis, following the spinoff, BD Medical Essentials represented 34% of revenue, the Interventional segment 28%, Connected Care 25%, and Biopharma 13%. International revenue accounts for 43% of the company's business.